CN BIO and iiCON collaborate to validate novel Covid-19 research tools

The Infection Innovation Consortium (iiCON) and organ-on-a-chip company (OOC) CN BIO have launched a research collaboration to validate the next generation of Covid-19 research tools.

Excerpt from the Press Release:

Led by the Liverpool School of Tropical Medicine (LSTM) iiCON is a £174 million programme that brings together industry, academia, and clinicals to accelerate the discovery, development and deployment of new treatments.

The research agreement will see LSTM validate CN Bio’s lung and lung-liver models, which have been designed to help improve the efficiency and accuracy of Covid-19 drug development.

Through Innovate UK, CN Bio was granted funding to build multi-cellular upper and lower human airway and multi-organ models that more accurately reflect the human environment and deliver more translatable data, in comparison to current in vivo studies.

The combination of in vitro and liver cultures should enable the multi-organ model to study inter-organ crosstalk effects, providing researchers with a deeper understanding of how Covid-19 affects various parts of the body.

The single and multi-organ models were developed for use with the company’s PhysioMimix plug-and-play, lab-benchtop MPS, enabling straightforward incorporation into current pre-clinical research projects investigating the next generation of Covid-19 therapeutics to treat and prevent the infection.

LSTM will now look to demonstrate the ability of the PhysioMimix systems to support the full viral life cycle of SARS-CoV-2 and facilitate testing with anti-viral compounds. Researchers will look to validate the PhysioMimix’s potential to identify PK/PD indices and PD Targets for the development of safe and efficacious dosing regimens of new antiviral therapeutics.

Click the button below to read the entire Press Release:

Continue Reading The Press Release